Updated data from ongoing clinical trial evaluating first-in-class antibody, IPH4102 will be presented at the EORTC CLTF 2018 Meeting in St Gallen, Switzerland, September 27-29, 2018.
- Title: IPH4102 in relapsed/refractory cutaneous T cell lymphoma (CTCL): Results of the first-in-human multicenter phase 1 study
- Date and time: September 29, 2018, 8:30 – 9:45
- Presentation number: 078
- Session: Oral presentation, Session 8 / Treatment and clinical cases
- Presenter: Martine Bagot, Principal Investigator and Head of the Dermatology Department at the Saint-Louis Hospital, Paris, France
- Location: Olma Messen Hall 9.2, St-Gallen, Switzerland